May 6 (Reuters) - Sanofi shareholders approved a move to drop Aventis from its name on Friday after buying U.S. biotech Genzyme, seven years after the merger of France's Sanofi-Synthelabo with Franco-German group Aventis.
The company had said on April 4, when it won control of Genzyme in a $20 billion deal, that it wanted to shorten the name as it was difficult to pronounce in several languages, including in China.
Sanofi Chief Executive Chris Viehbacher told shareholders at its annual meeting that the drugmaker would now slow down the rhythm of acquisitions, though it would still look at opportunities to expand in fast-growing emerging markets.
"(Sanofi) will continue to make acquisitions in emerging countries ... but we have a lot of things to do to make sure the (Genzyme) integrati
Saturday, May 07, 2011
Sanofi changes name, pace of acquisitions to slow | Reuters
via uk.reuters.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment